A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Inclusion Criteria: * Participants must have completed (neo) adjuvant endocrine therapy and have cancer return after at least 12 months or have de novo cancer that has spread to other organs at diagnosis * Participants must have 1 or more of the following: * A high grade tumor in tissue * Negative progesterone receptor (PR) status * Have cancer that has spread to the liver * Have a treatment-free interval (TFI) \<36 months * Participants must have HR+, HER2- breast cancer * Participants must have adequate organ function Exclusion Criteria: * Participants must not have cancer that has spread to other organs that has severely affected their function * Participants must not have cancer that has spread to the brain that is unstable or untreated * Participants must not have received endocrine therapy in the metastatic setting * Participants must not have known active infection * Participants must not have received prior endocrine therapy and had disease return within 12 months from completion of treatment * Participants must not have received prior treatment with any cyclin-dependent kinase (CDK) 4 \& 6 inhibitor or everolimus